|
WO2021070896A1
|
|
Halitosis alleviator or halitosis preventive
|
|
WO2020175253A1
|
|
Radiosensitizer
|
|
WO2020090570A1
|
|
Photo-damage reducing agent
|
|
US2020297674A1
|
|
Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
|
|
WO2018235728A1
|
|
Medicinal composition for ameliorating neuropathy
|
|
WO2018221291A1
|
|
Prophylactic or therapeutic agent for hyperactive bladder
|
|
WO2018193958A1
|
|
Enhancer of photodynamic effect in ala-pdt or ala-pdd
|
|
JP2019123682A
|
|
Enhancing of cancer or tumor therapeutic effect by plasma therapy
|
|
WO2018043240A1
|
|
Aqueous formulation containing 5-aminolevulinic acid or the like
|
|
WO2016204060A1
|
|
Enhancer of photodynamic effect in ala-pdt or ala-pdd
|
|
JP2017119072A
|
|
Medical light source device
|
|
EP3281629A1
|
|
Prophylactic/therapeutic agent for virus infections which comprises ala compound
|
|
JP2017160171A
|
|
AGENT FOR ENHANCING PpIX ACCUMULATION IN CANCER CELL
|
|
JP2017095396A
|
|
Neurodevelopmental disorder improving agent
|
|
JP2017079940A
|
|
Photodynamic therapy device and operation method therefor
|
|
EP3168296A1
|
|
Agent for improving normal development rate of fertilized eggs
|
|
CN107148215A
|
|
Organ preservative fluid
|
|
WO2015125732A1
|
|
Composition for prevention or treatment of treatment-resistant cancer
|
|
JP2016132658A
|
|
Diagnosis assistant method for malignant mesothelioma and diagnosis assistant agent
|
|
WO2014203833A1
|
|
Medicinal composition for promoting synthesis of protoporphyrin ix
|
